---
title: "Alnylam Pharmaceuticals Competitors"
description: "Who competes with Alnylam Pharmaceuticals, where the overlap occurs and how to compare the businesses without using a simplistic peer list."
canonical: https://www.getswoopr.com/stocks/companies/alnylam-pharmaceuticals/competitors/
source: "Swoopr Investment: https://www.getswoopr.com"
---

# Alnylam Pharmaceuticals Competitors & Competitive Landscape








## Direct answer



Alnylam Pharmaceuticals competes against Ionis, Arrowhead, and specialty biotech firms, but the overlap is not identical across every product or customer. The useful question is **which profit pool is contested**, which customer can switch, and what advantage is required to win.








## Ionis



Ionis overlaps with Alnylam Pharmaceuticals in one or more products, customers or budget categories. The most useful comparison is not market capitalization; it is product scope, customer value proposition, unit economics and the amount of capital required to compete. For a rigorous comparison, evaluate Ionis versus Alnylam Pharmaceuticals across customer overlap, product performance, pricing, distribution, switching costs, capital intensity and the ability to fund the next product or capacity cycle. A different business mix can make a simple margin or valuation comparison misleading.








## Arrowhead



Arrowhead overlaps with Alnylam Pharmaceuticals in one or more products, customers or budget categories. The most useful comparison is not market capitalization; it is product scope, customer value proposition, unit economics and the amount of capital required to compete. For a rigorous comparison, evaluate Arrowhead versus Alnylam Pharmaceuticals across customer overlap, product performance, pricing, distribution, switching costs, capital intensity and the ability to fund the next product or capacity cycle. A different business mix can make a simple margin or valuation comparison misleading.








## specialty biotech firms



specialty biotech firms overlaps with Alnylam Pharmaceuticals in one or more products, customers or budget categories. The most useful comparison is not market capitalization; it is product scope, customer value proposition, unit economics and the amount of capital required to compete. For a rigorous comparison, evaluate specialty biotech firms versus Alnylam Pharmaceuticals across customer overlap, product performance, pricing, distribution, switching costs, capital intensity and the ability to fund the next product or capacity cycle. A different business mix can make a simple margin or valuation comparison misleading.








## Competitive dimensions that matter



| Dimension | Question for Alnylam Pharmaceuticals |
| --- | --- |
| Product | Does Alnylam Pharmaceuticals's offering solve the customer problem better or more completely? |
| Price | Is pricing supported by differentiated value or merely by a favorable cycle? |
| Distribution | Can competitors reach the same customers with similar efficiency? |
| Switching cost | What economic, technical or organizational friction makes a change difficult? |
| Scale | Does scale lower cost, improve data, expand selection or support larger R&D budgets? |
| Capital intensity | How much cash must be committed to defend the position? |
| Innovation | Is product leadership sustained through measurable adoption and outcomes? |
| Regulation | Does regulation protect incumbents, raise cost, or create disruption risk? |








## How to tell whether the moat is strengthening



Do not label the company as having a "wide moat" without evidence. For Alnylam Pharmaceuticals, look for a combination of improving product revenue, patient growth, and R&D, resilient customer behavior and favorable movement in patient finding, and geographic expansion. If the company must continually cut price, overspend to retain customers or accept weaker returns, scale alone may not represent an advantage.








## Competitive warning signs



Competitive erosion can appear before revenue declines. Watch for slower adoption, weaker renewal or repeat activity, price concessions, increased customer acquisition cost, rising R&D just to maintain parity, loss of strategic partners, or a competitor setting the pace of the product roadmap.



For Alnylam Pharmaceuticals, the relevant warning signs are clinical failures, rare-disease commercialization, pricing, competition, and patent risk.








## Related pages



- [Alnylam Pharmaceuticals Investor Guide](https://www.getswoopr.com/stocks/companies/alnylam-pharmaceuticals/)
- [Alnylam Pharmaceuticals Metrics](https://www.getswoopr.com/stocks/companies/alnylam-pharmaceuticals/metrics/)
- [Alnylam Pharmaceuticals Risks](https://www.getswoopr.com/stocks/companies/alnylam-pharmaceuticals/risks/)
- [Nasdaq-100 companies](https://www.getswoopr.com/stocks/indexes/nasdaq-100/#constituents)








## References



1. [Nasdaq](https://www.nasdaq.com/market-activity/stocks/alny)
2. [SEC EDGAR: Full Text Search for ALNY](https://www.sec.gov/edgar/search/#/q=ALNY)
3. [Nasdaq](https://indexes.nasdaq.com/Index/Overview/NDX)
4. [Nasdaq](https://indexes.nasdaq.com/docs/Methodology_NDX.pdf)











**[Swoopr Editorial Team](https://www.getswoopr.com/authors/swoopr-editorial-team/)**



Swoopr's editorial team produces independent investment education content reviewed for accuracy and clarity. We do not provide personalized financial advice. See our [editorial policy](https://www.getswoopr.com/legal/editorial-policy/) and [corrections policy](https://www.getswoopr.com/legal/corrections-policy/).